No one with HIV infection has been cured, regardless of the development of effective antiretroviral therapy (ART). Nevertheless, stable remission or cure of infection is the ultimate goal of HIV therapy. The difficulties of lifelong therapy make it imperative to understand the obstacles to eradication of HIV infection, and to attempt to overcome them. In addition to improved antivirals, agents that induce expression of latent HIV but do not enhance de novo infection are needed. First, recent studies suggest that HIV infection may persist in a spectrum of CD4 memory cell populations, perhaps related to the stage of disease reached when viremia is suppressed by ART. Therefore, we must specifically characterize the frequency of persistent infection in memory cell subpopulations (eg. naive, central, transitional, effector), and investigate the potential differences in responsiveness to agents that perturb latency. This will be important information if future anti-latency therapies are to be effective in all memory cell subsets, and in all patient populations. Second, across the Deianey Collaboratory investigators will develop new approaches and molecules to disrupt and deplete latent HIV infection across a wide variety of model systems, and will discover new mechanisms that establish or maintain latent HIV infection. However to move these advances toward clinical translation, this project will contribute to the advances ofthe Collaboratory via studies in the ultimate model system - - resting CD4+ T cells obtained from aviremic, ART-treated patients.
Specific Aim I : The frequency of resting CD4+ T cell infection in central and transitional, and effector memory cell will differ in patients treated during acute or chronic HiV infection.
Specific Aim 1 1: Novel molecules will be discovered that alone or in synergy with other reagents (eg. SAHA) disrupt latency in the resting CD4+ T cells of HIV-infected aviremic,ART-treated patients.
Specific Aim III : Targeting restrictions to expression in the resting CD4+ T cells of HIV+ patients will induce viral outgrowth.

Public Health Relevance

Despite antiviral therapy, eradication of HIV infection is unachievable as the virus can establish latency in CD4+ cells. We seek to develop agents capable of inducing expression of quiescent HIV in these cells without enhancing new infection, so that persistent viral infection may be cleared. We will study novel compounds that can disrupt latent infection, to define their potency and efficacy, and seek new insight into the mechanisms of HIV latencv. and the cells that remain oersistentlv infected.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096113-03
Application #
8497444
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$1,946,445
Indirect Cost
$438,415
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Showing the most recent 10 out of 221 publications